Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

October 2022

Signaux de toxicité associés au sécukinumab : Une étude de pharmacovigilance basée sur la base de données du système de notification des effets indésirables de la Food And Drug Administration des États-Unis

Br J Clin Pharmacol. 2022 doi: 10.1111/bcp.15535

Zheng Y,

Guo X,

Chen C,

Chi L,

Guo Z,

Liang J,

Wei L,

Chen X,

Ye X,

He J

This study explored the clinical characteristics, outcomes, and time to onset of the four main toxicities of secukinumab with hypersensitivity identified as the most common toxicity.

Keywords:

After JAK Inhibitor Failure: To Cycle Or To Switch, That Is The Question – Data From The JAK-Pot Collaboration of Registries

Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-222835

Inanc N,

Leeb BF,

Rotar Z,

Data from the JAK-pot collaboration of registries show that cycling JAKinibs and switching to a bDMARD appear to have similar effectiveness, after failing the first JAKinib.

Keywords:

September 2022

Le sécukinumab dans l'arthrite liée à l'enthésite et le rhumatisme psoriasique juvénile : Essai de phase 3 randomisé, en double aveugle, contrôlé par placebo, avec arrêt de traitement

Ann Rheum Dis. 2022 2022 2022-222849

Ayaz NA,

Ozen S,

Scott C,

Zhu X,

Ruperto N; Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)

In the latest study by Brunner, et al. secukinumab demonstrated efficacy and safety in the JIA categories of ERA and JPsA. This phase 3 study aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA.

Keywords:

April 2022

Surveillance ORAL et innocuité des inhibiteurs de JAK : la théorie de la relativité

Nat Rev Rheumatol. 2022. Epub ahead of print doi: 10.1038/s41584-022-00767-7

Winthrop KL,

Cohen SB.

Putting the data into context, Winthrop, et al. conclude that the ORAL Surveillance data are not dissimilar to those from the original developmental programme, which suggested additional safety concerns at the 10 mg dosage and that resulted in the 5 mg twice daily dosage as the approved dose for RA.Following the recent results of the ORAL Surveillance (ORALSURV) study, and the consequent changes to the utilisation of JAKinibs, made by the regulatory authorities, Winthrop, et al. aim to put the O...